Equities research analysts forecast that ICU Medical, Incorporated (NASDAQ:ICUI) will report $329.30 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for ICU Medical’s earnings, with the highest sales estimate coming in at $329.60 million and the lowest estimate coming in at $329.00 million. ICU Medical reported sales of $95.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 244.2%. The firm is scheduled to announce its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that ICU Medical will report full year sales of $329.30 million for the current fiscal year, with estimates ranging from $1.24 billion to $1.25 billion. For the next financial year, analysts expect that the business will post sales of $1.34 billion per share. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.35. ICU Medical had a net margin of 2.79% and a return on equity of 4.81%. The business had revenue of $343.20 million for the quarter, compared to analysts’ expectations of $328.56 million. During the same period in the prior year, the firm earned $1.35 earnings per share. ICU Medical’s revenue was up 253.5% compared to the same quarter last year.
Shares of ICU Medical (NASDAQ ICUI) opened at $229.35 on Thursday. ICU Medical has a 52 week low of $131.35 and a 52 week high of $233.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65. The company has a market cap of $4,607.88, a P/E ratio of 148.93, a PEG ratio of 2.53 and a beta of 0.36.
In related news, Chairman Vivek Jain sold 97,795 shares of the stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $190.00, for a total value of $18,581,050.00. Following the transaction, the chairman now directly owns 67,680 shares in the company, valued at $12,859,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director George A. Lopez sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $205.83, for a total transaction of $1,029,150.00. Following the completion of the transaction, the director now owns 573,916 shares in the company, valued at $118,129,130.28. The disclosure for this sale can be found here. Insiders have sold 129,419 shares of company stock worth $25,454,700 over the last three months. 13.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ICUI. Janus Henderson Group PLC acquired a new position in ICU Medical in the second quarter valued at approximately $247,072,000. Vanguard Group Inc. lifted its holdings in ICU Medical by 16.3% in the second quarter. Vanguard Group Inc. now owns 1,304,282 shares of the medical instruments supplier’s stock valued at $224,989,000 after buying an additional 183,133 shares during the period. Point72 Asset Management L.P. acquired a new position in ICU Medical in the third quarter valued at approximately $22,246,000. Citadel Advisors LLC acquired a new position in ICU Medical in the third quarter valued at approximately $18,135,000. Finally, Segall Bryant & Hamill LLC acquired a new position in ICU Medical in the third quarter valued at approximately $12,589,000. Institutional investors and hedge funds own 78.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ICU Medical, Incorporated (ICUI) Expected to Announce Quarterly Sales of $329.30 Million” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3143701/icu-medical-incorporated-icui-expected-to-announce-quarterly-sales-of-329-30-million.html.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.